LNA-antisense rivals siRNA for gene silencing

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

LNA-antisense rivals siRNA for gene silencing. / Stenvang, Jan; Wengel, Jesper.

In: Current Opinion in Drug Discovery & Development, Vol. 7, No. 2, 03.2004, p. 188-94.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Stenvang, J & Wengel, J 2004, 'LNA-antisense rivals siRNA for gene silencing', Current Opinion in Drug Discovery & Development, vol. 7, no. 2, pp. 188-94.

APA

Stenvang, J., & Wengel, J. (2004). LNA-antisense rivals siRNA for gene silencing. Current Opinion in Drug Discovery & Development, 7(2), 188-94.

Vancouver

Stenvang J, Wengel J. LNA-antisense rivals siRNA for gene silencing. Current Opinion in Drug Discovery & Development. 2004 Mar;7(2):188-94.

Author

Stenvang, Jan ; Wengel, Jesper. / LNA-antisense rivals siRNA for gene silencing. In: Current Opinion in Drug Discovery & Development. 2004 ; Vol. 7, No. 2. pp. 188-94.

Bibtex

@article{051374d4f0524ddc96f45d09b11230ad,
title = "LNA-antisense rivals siRNA for gene silencing",
abstract = "Locked nucleic acid (LNA) is a class of nucleic acid analogs possessing unprecedented binding affinity toward complementary DNA and RNA while obeying the Watson-Crick base-pairing rules. For efficient gene silencing in vitro and in vivo, fully modified or chimeric LNA oligonucleotides have been applied. LNA oligonucleotides are commercially available, can be transfected using standard techniques, are non-toxic, lead to increased target accessibility, can be designed to activate RNase H, and function in steric block approaches. LNA-Antisense, including gapmer LNA containing a central DNA or phosphorothioate-DNA segment flanked by LNA gaps, rivals siRNA as the technology of choice for target validation and therapeutic applications.",
keywords = "Animals, Drug Design, Gene Silencing, Genetic Therapy, Humans, Oligonucleotides, Oligonucleotides, Antisense, RNA, Small Interfering, Ribonuclease H",
author = "Jan Stenvang and Jesper Wengel",
year = "2004",
month = mar,
language = "English",
volume = "7",
pages = "188--94",
journal = "Current Opinion in Drug Discovery and Development",
issn = "1367-6733",
publisher = "Current Drugs Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - LNA-antisense rivals siRNA for gene silencing

AU - Stenvang, Jan

AU - Wengel, Jesper

PY - 2004/3

Y1 - 2004/3

N2 - Locked nucleic acid (LNA) is a class of nucleic acid analogs possessing unprecedented binding affinity toward complementary DNA and RNA while obeying the Watson-Crick base-pairing rules. For efficient gene silencing in vitro and in vivo, fully modified or chimeric LNA oligonucleotides have been applied. LNA oligonucleotides are commercially available, can be transfected using standard techniques, are non-toxic, lead to increased target accessibility, can be designed to activate RNase H, and function in steric block approaches. LNA-Antisense, including gapmer LNA containing a central DNA or phosphorothioate-DNA segment flanked by LNA gaps, rivals siRNA as the technology of choice for target validation and therapeutic applications.

AB - Locked nucleic acid (LNA) is a class of nucleic acid analogs possessing unprecedented binding affinity toward complementary DNA and RNA while obeying the Watson-Crick base-pairing rules. For efficient gene silencing in vitro and in vivo, fully modified or chimeric LNA oligonucleotides have been applied. LNA oligonucleotides are commercially available, can be transfected using standard techniques, are non-toxic, lead to increased target accessibility, can be designed to activate RNase H, and function in steric block approaches. LNA-Antisense, including gapmer LNA containing a central DNA or phosphorothioate-DNA segment flanked by LNA gaps, rivals siRNA as the technology of choice for target validation and therapeutic applications.

KW - Animals

KW - Drug Design

KW - Gene Silencing

KW - Genetic Therapy

KW - Humans

KW - Oligonucleotides

KW - Oligonucleotides, Antisense

KW - RNA, Small Interfering

KW - Ribonuclease H

M3 - Journal article

C2 - 15603252

VL - 7

SP - 188

EP - 194

JO - Current Opinion in Drug Discovery and Development

JF - Current Opinion in Drug Discovery and Development

SN - 1367-6733

IS - 2

ER -

ID: 59323974